Paclitaxel → HCID 178476617, 화합물
반응식
[CH2:1]1[CH2:4][C:3]2([C:10](=[O:11])[O:9][Pt:8]([NH3:13])([NH3:12])[O:7][C:5]2=[O:6])[CH2:2]1.[CH3:14][C:15]1[C@@H:32]([O:33][C:34]([C@H:36]([OH:53])[C@@H:37]([NH:44][C:45]([C:47]2[CH:48]=[CH:49][CH:50]=[CH:51][CH:52]=2)=[O:46])[C:38]2[CH:39]=[CH:40][CH:41]=[CH:42][CH:43]=2)=[O:35])[CH2:31][C@:27]2([OH:54])[C:28]([CH3:30])([CH3:29])[C:16]=1[C@@H:17]([O:72][C:73]([CH3:75])=[O:74])[C:18]([C@@:20]1([CH3:71])[C@H:25]([C@@H:26]2[O:55][C:56]([C:58]2[CH:59]=[CH:60][CH:61]=[CH:62][CH:63]=2)=[O:57])[C@:24]2([O:66][C:67]([CH3:69])=[O:68])[CH2:64][O:65][C@@H:23]2[CH2:22][C@@H:21]1[OH:70])=[O:19]>>[CH2:1]1[CH2:4][C:3]2([C:5](=[O:6])[O:7][Pt:8]([NH3:13])([NH3:12])[O:9][C:10]2=[O:11])[CH2:2]1.[CH3:14][C:15]1[C@@H:32]([O:33][C:34]([C@H:36]([OH:53])[C@@H:37]([NH:44][C:45]([C:47]2[CH:52]=[CH:51][CH:50]=[CH:49][CH:48]=2)=[O:46])[C:38]2[CH:39]=[CH:40][CH:41]=[CH:42][CH:43]=2)=[O:35])[CH2:31][C@:27]2([OH:54])[C:28]([CH3:29])([CH3:30])[C:16]=1[C@@H:17]([O:72][C:73]([CH3:75])=[O:74])[C:18]([C@@:20]1([CH3:71])[C@H:25]([C@@H:26]2[O:55][C:56]([C:58]2[CH:63]=[CH:62][CH:61]=[CH:60][CH:59]=2)=[O:57])[C@:24]2([O:66][C:67]([CH3:69])=[O:68])[CH2:64][O:65][C@@H:23]2[CH2:22][C@@H:21]1[OH:70])=[O:19]참가 물질
3
실험 절차
Control mice received the saline vehicular control by interperitoneal (i.p.) injection every day for 12 days. A constant dose of SorC13 (300 mg/kg) was used throughout the experiments and injected i.p. every day for 12 days. Low (20 mg/kg carboplatin, 6 mg/kg paclitaxel), medium (40 mg carboplatin, 12 mg/kg paclitaxel) and high (60 mg/kg carboplatin, 24 mg/kg paclitaxel) doses of CAT were injected i.p. on days 1, 4, 8 and 11 as set out in Table 10.
후처리
- customfor 12 days
- waiton days 1, 4, 8 and 11 as set out in Table 10